Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Azacytidine in MF and MDS/MPN
NCT01787487Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2013
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ruxolitinib and azacitidine in myelofibrosis (MF) and myelodysplastic/myeloproliferative neoplasm (MDS/MPN) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Objective Response Rate at 24 weeks. Started Mar 2013; status: completed.
02
Drugs
ruxolitinibazacitidine
03
Conditions
myelofibrosis (MF)myelodysplastic/myeloproliferative neoplasm (MDS/MPN)
Beyond the preview
Go deeper on NCT01787487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01787487.